Transcript Slide 1

SARC Developmental Therapeutics
SARC Developmental Therapeutics
Committee Update
Chand Khanna
Chawla/Rosenfeld Developmental Therapeutics
Symposium
“Open Science: Biology to Therapy”
SARC-DTC Members
• Chand Khanna, DVM, PhD (NCI) Chair
• Poul Sorenson, MD, PhD (UBC/BC Cancer Agency)
• Raphael Pollock, MD, PhD (MD Anderson)
• Kapil Dhingra, MD (KAPital Consulting)
• Jeffrey Trent, PhD (Tgen)
• David Kirsch, MD, PhD (Duke University)
• Peter Houghton, PhD (Ohio State University)
• *Shreyaskumar Patel, MD (MD Anderson)
• *Denise Reinke, MS, NP (SARC)
*Ex Officio
SARC Developmental
Therapeutics Committee (DTC
To establish an integrated and facile SARC effort
closely aligned with the interests of pharmaceutical
industry that can provide preclinical and translational
data in sarcoma
SARC-DTC Preclinical and Translational Infrastructure
SARC-DTC work
scope managed
through a research
contract with
Sponsors
SARC –
Development
Therapeutics
Committee
Investigative
Centers engaged by
SARC-DTC through
Master Services
Agreement
Investigative Centers Providing
SARC-DTC Services
Sponsoring
Pharmaceutical
Partner
SARC-DTC
Preclinical
and
Translational
Study Report
Investigative Centers
defined through SARCDTC
SARC-DTC Preclinical and Translational Infrastructure
SARC –
Development
Therapeutics
Committee
Current Investigative Center
Portfolio
>50 Sarcoma Cell Lines
>30 Sarcoma Xenografts
Sarcoma tissues
Frozen tissues
Sarcoma Tissue Arrays
Genomics (SARComics Portal)
Investigative
Centers engaged by
SARC-DTC through
Master Services
Agreement
Investigative Centers Providing
SARC-DTC Services
Investigative Centers
defined through SARCDTC
SARC-DTC Preclinical and Translational Infrastructure
 Expansion of drug opportunities/assets for SARC clinical
development through the development of preclinical and
translational data in sarcoma
 Prioritization of SARC developmental path
 Opportunity to inform phase 1 and phase 2 transitions within
SARC clinical development path
 Please help spread the word to interested parties of the
opportunities to generate preclinical data in sarcoma
through SARC
SARC-Omics Portal
 To provide sarcoma investigators a consolidated portal
for curation and viewing of “omics” data.

To be developed through a collaboration of TGEN and SARC
 Screen shots expected at the SARC/CTOS 2013 in a
matter of minutes…
Chawla/Rosenfeld Developmental
Therapeutics Symposium
SARC Developmental Therapeutics
Committee Update
Chand Khanna
Chawla/Rosenfeld Developmental Therapeutics
Symposium
Chawla Rosenfeld Developmental
Therapeutics Symposium
Open Science: Biology to Therapy
A Case for Open-Source Drug Discovery – J. Bradner
Anti-angiogenic activity of JQ1 in Sarcomas – H. Bid
The Sarcoma Data Portal: Making High Content Sarcoma Datasets Available For
All Users – J. Keats
Discussion (20 min)